FindMyKOL
Clinical trialNCT07569250Not, yet, recruitingInterventional

Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization

SponsorUniversity of Colorado, DenverEnrollment7,220Colorectal Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this interventional study is to create and test a comprehensive and low burden text message program within existing Community Health Centers (CHC) electronic records system to encourage patients to complete at home colorectal cancer (CRC) screening and to make sure they get follow-up care if their results are abnormal. First, the investigators will learn from clinic staff and patients what their needs and preferences are in terms of use of technology. This information will be used to design the text messages program. * Clinic patients will participate in focus groups * Clinic staff will participate in interviews Second, the investigators will test a series of different message versions in two batches (experiments): * Clinic patients with orders for an at-home colorectal cancer screening kit will receive the different message versions. * In the first batch, the messages that get the most engagement from patients will be selected to be used in the second experiment. * In the second batch, the investigators will test which messages lead to the most colorectal cancer screening completion. * This will be rolled-out within the clinics existing electronic record system. The study team will not receive any information that will identify individual patients. Lastly, the investigators will check again with clinic staff to learn how the program performed, and what would be needed to continue using the text message program in the long run. -Clinic staff will participate in interviews and surveys.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Kasisomayajula Viswanath, PhD
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Adjoa Anyane-Yeboa, MD, MPH
  • the Massachusetts League of Community Health Center, Inc.

    Boston, Massachusetts, United States

    Susan Dargon-Hart
  • University of Texas Southwestern Medical Center

    Dallas, Texas, United States

    Lynn Ibekwe-Agunanna, MPH, PhD

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2026
Primary completion
31 Oct 2031
Completion
31 Jan 2032
Last update posted
10 Jul 2026
Registered enrollment
7,220
Registry id
NCT07569250

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.